AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

British drugmaker AstraZeneca PLC (NYSE: AZN) has pledged that it will not profit from its under-development COVID-19 vaccine until the pandemic is over. According to the Financial Times, that timeline may be a lot shorter than most people anticipated.

AstraZeneca Could Start Profiting From COVID-19 Vaccine As Soon As July: FT

Invesco DWA SmallCap Momentum ETF

Inovio Pharmaceuticals

iShares Russell 2000 Growth ETF

iShares Morningstar Small-Cap Growth ETF

Johnson & Johnson

Merck

Moderna

Pfizer

Vanguard Small-Cap Growth

Vanguard Russell 2000 Growth 

Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.

Here's Why Small-Cap ETFs Are Hitting New Highs

BioNTech SE

Pharmaceutical companies developing COVID-19 vaccines should wait two months after late-stage studies conclude to submit an application for an emergency use authorization to the Food and Drug Administration, the regulator said Tuesday.

FDA to require 2-month follow-up period for COVID-19 vaccines before authorization

Pfizer and BioNTech will share the data from their phase 3 clinical trial with the European Medicines Agency as it comes in.

EU Regulators Undertake Rolling Review of Another Coronavirus Vaccine Candidate

This one-time Operation Warp Speed favorite isn't even moving at a snail's speed in America.

AstraZeneca's Coronavirus Vaccine Is Already Being Reviewed for Approval in Canada and Europe. Why Not in the U.S.?

GlaxoSmithKline

NVIDIA

Nvidia Corporation (NASDAQ: NVDA) said Monday it is working to build the United Kingdom’s most powerful supercomputer, which it will provide to healthcare researchers working on COVID-19. What Happened: The “Cambridge-1” is expected to come online by the end of 2020 and is expected to be ranked 29 among the TOP500 list of the world’s most powerful supercomputers, Nvidia said in a statement.

COVID-19 Vaccine Makers AstraZeneca, GSK To Get First Access To Nvidia's 'Cambridge-1' Supercomputer

AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in Japan resume. The U.S. study remains on hold.

AstraZeneca Resumes Japan Study on Coronavirus Vaccine Candidate

Abbott Labs

These two companies are making headway against the pandemic in key areas.

2 Top Coronavirus Stocks to Buy Right Now

Novavax

One offers massive potential for gains. The other offers security.

Should You Buy Biotech or Big Pharma in the COVID-19 Vaccine Race?

Sometimes it pays to know about the nuts and bolts of the clinical trial process.

Everything Investors Need to Know About Investigational New Drug Submissions

The rolling review should help the pharma get its vaccine approved quicker.

Canada Begins Reviewing AstraZeneca's Coronavirus Vaccine, U.S. Study Still Not Restarted

AstraZeneca's (AZN) Phase 3 vaccine trials are generating little or no buying interest.

COVID Speculators Walking Away From AstraZeneca (AZN)

The odds that AZD1222 will win swift approval in the EU seem to be rising, but in the U.S., it might be a different story.

European Regulators Begin Accelerated Review of AstraZeneca's COVID-19 Vaccine Candidate, but FDA Widens Its Investigation Into Clinical Trial Illness

AstraZeneca Plc’s (NYSE: AZN) coronavirus vaccine development program could hit by further delays, as the Food and Drug Administration has widened the scope of its probe into the halted trial, Reuters reported Wednesday. What Happened: The federal agency is inquiring whether side effects similar to the one seen in the COVID-19 vaccine trial — transverse myelitis — also emerged in trials of other vaccines designed by Oxford University, AstraZeneca's partner, Reuters said, citing people familiar with the matter.

AstraZeneca's COVID-19 Vaccine Trial Delays May Worsen As FDA Widens Investigation

Gilead Sciences

5 Vaccine Stocks to Buy Now

The roaring 2020s started with a red-hot market that melted down into a 35% sell-off in less than a month.

4 Companies in Late-Stage Coronavirus Vaccine Testing: Will Big Pharma Win the Race?

Canada is the latest country to enter a big vaccine-delivery commitment with AstraZeneca.

AstraZeneca Signs Deal With Canada to Provide 20 Million Coronavirus Vaccine Doses

European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters.

Exclusive: AstraZeneca gets partial immunity in low-cost EU vaccine deal

Global X Cybersecurity ETF

DraftKings

DocuSign

Amplify Mobile Payments ETF

Proshares Online Retail ETF

Walmart

The novel coronavirus pandemic produced some clear winners. And here are seven companies to invest in that adjusted well to the "new normal.

7 Companies to Invest in That Pivoted Perfectly in the Pandemic

AstraZeneca's late-stage coronavirus vaccine trials in the U.S. remains on hold as federal investigators seek "answers to important questions," HHS Secretary Alex Azar told CNBC.

AstraZeneca coronavirus vaccine trials remains on hold in the U.S., HHS chief Azar says

Today, investors are better prepared to choose potential winners.

Now Is the Perfect Time to Invest in Coronavirus Vaccine Stocks

Scientists are questioning why AstraZeneca Plc’s (NYSE: AZN) COVID-19 vaccine clinical trials remain paused in the United States even as other countries move forward.

Scientists Question Why AstraZeneca COVID-19 Vaccine Trial Remains On Hold In US

AstraZeneca's (AZN) PARP inhibitor, Lynparza, nears approval as a treatment for prostate cancer, and first-line maintenance treatment for ovarian cancer in combination with Avastin in Europe.

AstraZeneca's Lynparza Gets CHMP Nod for Two New Indications

Moderna is in the spotlight for its vaccine candidate, but you might want to look to this pharma giant for reliable returns instead.

Forget Moderna -- This Is a Stronger Coronavirus Stock

INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca's biologics therapeutics, which could be increased to $545.6 million.

Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply

News for AstraZeneca Stock (AZN)